ACVR1 and ovarian carcinoma: Pharmacological targeting of ALK1 in a mouse model for endocrine pancreatic tumorigenesis and of ALK2 in ovarian cancer has recently been proven to be able to reduce tumor growth and angiogenesis [33,34].